New Zealand markets closed

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.1500+0.0100 (+0.88%)
At close: 03:59PM EST
1.1800 +0.03 (+2.61%)
After hours: 04:43PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 25.92M
Enterprise value -58.19M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.33
Enterprise value/revenue N/A
Enterprise value/EBITDA 1.33

Trading information

Stock price history

Beta (5Y monthly) 1.33
52-week change 3-52.08%
S&P500 52-week change 3-11.32%
52-week high 35.8000
52-week low 30.9620
50-day moving average 31.1657
200-day moving average 31.6857

Share statistics

Avg vol (3-month) 353.61k
Avg vol (10-day) 359.43k
Shares outstanding 523.56M
Implied shares outstanding 6N/A
Float 86.32M
% held by insiders 10.15%
% held by institutions 185.23%
Shares short (14 Nov 2022) 4328.91k
Short ratio (14 Nov 2022) 46.57
Short % of float (14 Nov 2022) 41.90%
Short % of shares outstanding (14 Nov 2022) 41.40%
Shares short (prior month 13 Oct 2022) 485.55k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-24.04%
Return on equity (ttm)-44.62%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -44.24M
Net income avi to common (ttm)-44.22M
Diluted EPS (ttm)-1.8860
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)90.4M
Total cash per share (mrq)3.84
Total debt (mrq)6.29M
Total debt/equity (mrq)8.01
Current ratio (mrq)7.76
Book value per share (mrq)3.33

Cash flow statement

Operating cash flow (ttm)-39.74M
Levered free cash flow (ttm)-23.75M